Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Talking Healthtech

- PMLiVE

Personalised cancer medicines showcased in BBC investigation

Panorama looked at cutting-edge science and the new generation of oncology drugs

- PMLiVE

Melanoma charity uses shock tactics in new awareness campaign

Mollie's Fund strives to educate sunbed users about the skin cancer

- PMLiVE

NICE consults on reducing melanoma cases

New guidance set to focus on diagnosing and managing the skin cancer  

- PMLiVE

British Skin Foundation launches Valentine’s cancer campaign

Encourages public to check the moles of their loved ones

Bristol-Myers Squibb (BMS) building

BMS cancer drug Opdivo gains US melanoma licence

Therapeutic vaccine can now be used against the deadliest form of skin cancer

- PMLiVE

Roche and Exelixis file melanoma duo in US

Combination of cobimetinib and Zelboraf improved progression-free survival by 9.9 months

Bristol-Myers Squibb (BMS) building

BMS’ PD-1 blocker Opdivo aces lung cancer trial

41% of treated patients alive after 12 months

- PMLiVE

Merck & Co’s cancer drug Keytruda gaining traction in US

Anti-PD-1 drug is used in around three quarters of eligible patients in US just weeks after FDA approval

- PMLiVE

NICE backs GSK’s Tafinlar for skin cancer

Joins Yervoy and Zelboraf as a recommended melanoma treatment

US approval for Philips’ telehealth applications

The programmes give clinicians real-time access to health data

Bristol Myers Squibb logo

First phase III data for BMS’ anti-PD1 nivolumab

Opdivo shows promise in melanoma study

- PMLiVE

NICE fast-tracks GSK’s skin cancer drug Tafinlar

But only on condition the company cuts its price

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links